Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program.
Ji L, Bonnet F, Charbonnel B, Gomes MB, Kosiborod M, Khunti K, Nicolucci A, Pocock S, Rathmann W, Shestakova MV, Shimomura I, Watada H, Fenici P, Hammar N, Hashigami K, Macaraeg G, Surmont F, Medina J. Ji L, et al. Among authors: surmont f. J Diabetes Complications. 2017 Jul;31(7):1188-1196. doi: 10.1016/j.jdiacomp.2017.03.011. Epub 2017 Apr 5. J Diabetes Complications. 2017. PMID: 28499961 Free article.
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
Kosiborod M, Lam CSP, Kohsaka S, Kim DJ, Karasik A, Shaw J, Tangri N, Goh SY, Thuresson M, Chen H, Surmont F, Hammar N, Fenici P; CVD-REAL Investigators and Study Group. Kosiborod M, et al. Among authors: surmont f. J Am Coll Cardiol. 2018 Jun 12;71(23):2628-2639. doi: 10.1016/j.jacc.2018.03.009. Epub 2018 Mar 11. J Am Coll Cardiol. 2018. PMID: 29540325 Free article. Clinical Trial.
Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program).
Kosiborod M, Gomes MB, Nicolucci A, Pocock S, Rathmann W, Shestakova MV, Watada H, Shimomura I, Chen H, Cid-Ruzafa J, Fenici P, Hammar N, Surmont F, Tang F, Khunti K; DISCOVER investigators. Kosiborod M, et al. Among authors: surmont f. Cardiovasc Diabetol. 2018 Nov 28;17(1):150. doi: 10.1186/s12933-018-0787-8. Cardiovasc Diabetol. 2018. PMID: 30486889 Free PMC article.
Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study.
Gomes MB, Rathmann W, Charbonnel B, Khunti K, Kosiborod M, Nicolucci A, Pocock SJ, Shestakova MV, Shimomura I, Tang F, Watada H, Chen H, Cid-Ruzafa J, Fenici P, Hammar N, Surmont F, Ji L; DISCOVER investigators. Gomes MB, et al. Among authors: surmont f. Diabetes Res Clin Pract. 2019 May;151:20-32. doi: 10.1016/j.diabres.2019.03.024. Epub 2019 Mar 20. Diabetes Res Clin Pract. 2019. PMID: 30904743 Free article.
Eligibility of patients with type 2 diabetes for sodium-glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study.
Pintat S, Fenici P, Hammar N, Ji L, Khunti K, Medina J, Tang F, Wittbrodt E, Surmont F. Pintat S, et al. Among authors: surmont f. BMJ Open Diabetes Res Care. 2019 Mar 21;7(1):e000627. doi: 10.1136/bmjdrc-2018-000627. eCollection 2019. BMJ Open Diabetes Res Care. 2019. PMID: 31114700 Free PMC article.
Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme.
Nicolucci A, Charbonnel B, Gomes MB, Khunti K, Kosiborod M, Shestakova MV, Shimomura I, Watada H, Chen H, Cid-Ruzafa J, Fenici P, Hammar N, Surmont F, Tang F, Pocock S. Nicolucci A, et al. Among authors: surmont f. Diabetes Obes Metab. 2019 Nov;21(11):2474-2485. doi: 10.1111/dom.13830. Epub 2019 Aug 5. Diabetes Obes Metab. 2019. PMID: 31297947 Free PMC article.
Socioeconomic factors associated with hypoglycaemia in patients starting second-line glucose-lowering therapy: The DISCOVER study.
Rathmann W, Charbonnel B, Gomes MB, Hammar N, Khunti K, Kosiborod M, Kuss O, Shestakova MV, Watada H, Shimomura I, Tang F, Cid-Ruzafa J, Chen H, Fenici P, Surmont F, Ji L; DISCOVER investigators. Rathmann W, et al. Among authors: surmont f. Diabetes Res Clin Pract. 2020 Jul;165:108250. doi: 10.1016/j.diabres.2020.108250. Epub 2020 Jun 10. Diabetes Res Clin Pract. 2020. PMID: 32531326
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study.
Kohsaka S, Lam CSP, Kim DJ, Cavender MA, Norhammar A, Jørgensen ME, Birkeland KI, Holl RW, Franch-Nadal J, Tangri N, Shaw JE, Ilomäki J, Karasik A, Goh SY, Chiang CE, Thuresson M, Chen H, Wittbrodt E, Bodegård J, Surmont F, Fenici P, Kosiborod M; CVD-REAL 2 Investigators and Study Group. Kohsaka S, et al. Among authors: surmont f. Lancet Diabetes Endocrinol. 2020 Jul;8(7):606-615. doi: 10.1016/S2213-8587(20)30130-3. Lancet Diabetes Endocrinol. 2020. PMID: 32559476
Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the DISCOVER study.
Patel KK, Gomes MB, Charbonnel B, Chen H, Cid-Ruzafa J, Fenici P, Hammar N, Ji L, Kennedy KF, Khunti K, Kosiborod M, Pocock S, Shestakova MV, Shimomura I, Surmont F, Watada H, Arnold SV. Patel KK, et al. Among authors: surmont f. Diabetes Obes Metab. 2021 Jan;23(1):39-48. doi: 10.1111/dom.14180. Epub 2020 Sep 22. Diabetes Obes Metab. 2021. PMID: 32845558 Free PMC article.
33 results